Z

Zymeworks
D

ZYME

14.280
USD
0.61
(4.46%)
Market Closed
Volume
20,124
EPS
-1
Div Yield
-
P/E
-10
Market Cap
983,571,071
OverviewSignalsIdeasNews
Related Instruments
    A
    ADAP
    -0.00320
    (-0.54%)
    0.58680 USD
    B
    BEAM
    -2.275
    (-8.65%)
    24.035 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    F
    FATE
    -0.04500
    (-2.17%)
    2.02500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    More
News

Title: Zymeworks

Sector: Healthcare
Industry: Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.